Subscribe To
3 reasons to buy eli lilly, and 1 reason to sell
Eli Lilly's prospective drugs and existing obesity/diabetes medicines are strong. The company's dividen...
July 11, 2023, 5:34 am
The case for novo nordisk: growth, dividends, and a new treatment frontier
Novo Nordisk, a global healthcare company, is expected to see significant growth due to its focus on Anti-obes...
July 10, 2023, 9:59 pm
Viking therapeutics (vktx) surges 64% year to date: here's why
The rising share price of Viking Therapeutics (VKTX) is attributable to the successful development of the company's pipeline candidates, targeting dis...
July 10, 2023, 11:00 am
Can eli lilly's (lly) continue its ride on obesity drug wave?
Lilly (LLY) continues to raise the bar on obesity drugs as latest data show that participants treated w...
July 5, 2023, 11:32 am
Varicose vein treatment market trends: addressing the rising obesity rates | future market insights, inc.
The increasing prevalence of obesity across geographies is propelling the growth of the Varicose Vein T...
July 3, 2023, 1:30 am
Pfizer just canned one of its ozempic killers. what's next?
Pfizer discontinued one of its candidates to treat diabetes and obesity. Even if it hadn't been discont...
July 1, 2023, 7:55 am
Eli lilly: miracle drug progress offers shareholders more upside
Eli Lilly and Company continues to make impressive progress when it comes to its obesity and diabetes m...
June 30, 2023, 10:23 pm
Is pfizer stock a buy or a sell on new challenges in obesity treatment?
Is Pfizer stock a buy or a sell after scrapping its once-daily pill for obesity treatment? Is PFE stock...
June 29, 2023, 2:43 pm
Pfizer obesity and diabetes drug danuglipron faces major challenges in coming to market, analysts warn
The path to market for Pfizer's drug danuglipron (danu) for obesity and type 2 diabetes looks “extrem...
June 27, 2023, 2:57 pm
Lilly, pfizer and others are working on obesity pills. what to know.
Lilly investors are upbeat on injectable weight-loss treatment Mounjaro, but the pills—easier to take, cheaper to make—might have the biggest long...
June 27, 2023, 1:35 pm
Pfizer (pfe) stock down on halting development of obesity drug
Shares of Pfizer's (PFE) fell 3.7% on Monday after management's decision to terminate the development of an experimental ...
June 27, 2023, 12:03 pm
Why eli lilly stock briefly popped today
Eli Lilly may have a best-in-class obesity care asset. In a mid-stage study, the drugmaker's weight los...
June 27, 2023, 11:33 am
Eli lilly stock nabs record on obesity drug trial data
Eli Lilly And Co (NYSE:LLY) released mid-stage trial data earlier today showing its obesity drug cand...
June 27, 2023, 11:08 am
Factbox: weight-loss drugs: the next gold rush
Drug developers are chasing an obesity drug gold rush that may be worth up to $100 billion by rolling o...
June 27, 2023, 10:56 am
Eli lilly shares gain after investigational obesity treatment helps patients lose up to 58 pounds, on average
Shares of Eli Lilly & Co. LLY, -1.33% gained 1.6% premarket on Tuesday after the company released new data late Monday on its investigational ...
June 27, 2023, 7:53 am
New developments in weight-loss drugs: novo nordisk, eli lilly & pfizer advance studies
Dr. Angela Fitch, Knownwell chief medical officer and president of obesity Medicine Association, joins ...
June 27, 2023, 7:40 am
Eli lilly stuns doctors as obesity drug sparks 24% weight loss
A new drug to tackle obesity cut the weight of participants by an average of 58 pounds at the end of it...
June 27, 2023, 4:01 am
Why shares of structure therapeutics rose monday
The clinical-stage biotech's lead therapy is designed to treat diabetes and obesity. Structure has enou...
June 26, 2023, 9:05 pm
Terns pharmaceuticals highlights new preclinical data for tern-601 program in obesity at the ada’s 83rd annual scientific session and upcoming events
TERN-601 significantly improved glucose tolerance, suppressed food intake and slowed gastric emptying in a preclinical transgenic mouse model Company ...
June 26, 2023, 8:05 pm
obesity weight loss market will remain a duopoly between novo nordisk and eli lilly: bofa's meacham
Geoff Meacham, Bank of America Securities, joins 'Fast Money to discuss the state of the weight-loss drug market as Eli Lilly and Novo Nordisk compete...
June 26, 2023, 6:49 pm